Advertisement
ALT vs OGEN
Which Stock Would AI Choose? Altimmune (ALT) vs. Oragenics (OGEN) Stock Comparison
Key Takeaways
- Different stages of clinical development: ALT is a late-stage biopharmaceutical company moving its lead candidate toward Phase 3 trials, while OGEN remains in earlier Phase IIa testing.
- Balance-sheet contrast: Altimmune holds roughly $535 million in cash and short-term investments, while Oragenics carries a going-concern warning and is addressing listing-standard deficiencies.
- Different therapeutic targets: ALT focuses on liver diseases, while OGEN targets concussion and traumatic brain injury through an intranasal delivery platform.
- Risk profiles differ sharply: OGEN trades at a sub-$1 price with higher volatility and financing risk, whereas ALT has stronger institutional backing and a funded runway into 2029.
- Catalysts ahead: Both companies have near-term data and regulatory milestones that could influence sentiment in the coming quarters.
- For deeper coverage of each name, visit ALT Major News and ALT Today's Price Move, as well as OGEN Major News and OGEN Today's Price Move.
- Explore Trending AI Robots to see which AI-driven trading strategies are currently positioned across these and other tickers.
Introduction
Both ALT (Altimmune) and OGEN (Oragenics) are clinical-stage biotechnology companies, yet they occupy very different positions within the sector. Comparing them highlights how development stage, balance-sheet strength, and therapeutic focus can shape relative performance and market positioning even among companies with no marketed products. This stock comparison is most relevant to traders and investors evaluating speculative biotech names where clinical milestones, financing events, and regulatory signals—rather than revenue—drive price behavior. Understanding the contrasts between a well-capitalized late-stage developer and a thinly traded early-stage microcap can help clarify the trade-offs between potential upside and downside risk.
ALT Overview and Recent Performance
Altimmune is a late clinical-stage biopharmaceutical company developing pemvidutide, an investigational glucagon/GLP-1 (glucagon-like peptide-1) dual receptor agonist, for serious liver diseases including MASH (metabolic dysfunction-associated steatohepatitis), AUD (alcohol use disorder), and ALD (alcohol-associated liver disease). The company has gained regulatory recognition for its lead program, including FDA (U.S. Food and Drug Administration) Breakthrough Therapy Designation in MASH.
In recent weeks, Altimmune has strengthened its financial position materially. The company completed an oversubscribed public offering that generated $225 million in gross proceeds, bringing cash and short-term investments to approximately $535 million as of late April 2026. Management has indicated this funding is expected to support operations into 2029. The company also announced board appointments aimed at supporting its transition to a late-stage, potentially commercial organization. Near-term catalysts include topline data from the Phase 2 RECLAIM trial in AUD and the planned initiation of the global Phase 3 PERFORMA trial in MASH during the second half of 2026. Despite these advances, shares have experienced downward pressure year to date, reflecting the dilutive impact of capital raises alongside broader biotech sentiment.
OGEN Overview and Recent Performance
Oragenics is a clinical-stage biopharmaceutical company advancing brain-targeted therapeutics through a proprietary intranasal delivery platform. Its lead candidate, ONP-002, is an intranasal neurosteroid being developed as a potential first-in-class treatment for concussion and mTBI (mild traumatic brain injury)—conditions that affect an estimated 69 million people globally each year and currently have no approved pharmacological therapy.
Recent market activity has reflected the company's earlier development stage and tighter financial position. Oragenics has been progressing a Phase IIa feasibility trial in Australia, recently activating a third clinical site and dosing nine participants across active sites. The company has also engaged with the FDA through a Type B meeting request as it works toward submitting an IND (Investigational New Drug) application by the end of 2026. However, sentiment has been weighed down by financial considerations: the company's 2025 annual audit included a going-concern explanatory paragraph, and in late August 2026 it received a deficiency letter from NYSE American related to stockholders' equity listing standards. Shares trade below $1, and price movement has been volatile, consistent with a thinly capitalized microcap awaiting clinical validation.
Trending AI Robots
Tickeron operates hundreds of AI Trading Bots that collectively trade thousands of different tickers, but not every bot suits every market environment. The Trending AI Robots page curates only the strategies best aligned with current market conditions, helping traders filter signal from noise. These bots vary widely in trading style, strategy, timeframe, performance statistics, and the specific sets of tickers they monitor—ranging from short-term momentum approaches to longer-horizon trend-following systems. By focusing on a smaller, performance-screened selection rather than the full catalog, the page gives investors a more actionable starting point for evaluating automated strategies. If you are interested in how AI-driven systems are positioning around names like ALT and OGEN, exploring the Trending AI Robots section can offer useful context.
Head-to-Head Comparison
The most significant contrast between the two companies is development stage and capital position. Altimmune is advancing a late-stage program with a substantially funded balance sheet and a runway extending to 2029, while Oragenics is in Phase IIa with a going-concern flag and active listing-compliance work. This difference in financial footing directly influences risk: OGEN carries materially higher dilution and delisting risk, whereas ALT's financing has been institutional-led and oversubscribed.
Therapeutic focus also differs. ALT targets large, well-validated liver-disease markets where GLP-1-based mechanisms have drawn intense investor interest, but it also faces substantial competition and the burden of large, expensive pivotal trials. OGEN addresses a relatively unserved neurological niche—concussion—with no approved drug, which offers a potentially first-in-class opportunity but also unproven commercial pathways. Growth drivers, momentum, and sector exposure therefore diverge: ALT is more sensitive to liver-disease clinical readouts and competitive dynamics, while OGEN is driven by early-stage enrollment progress and regulatory milestones.
Tickeron AI Verdict
Based on observable factors such as trend consistency, financial stability, and the quality of near-term catalysts, Tickeron's AI framework would likely view ALT as the relatively more stable positioning among the two. Altimmune's stronger balance sheet, regulatory designations, and clearly defined late-stage catalysts present a more defined risk-reward profile than Oragenics' earlier-stage, higher-uncertainty setup. That said, OGEN could exhibit greater relative upside on positive clinical or regulatory news given its smaller capitalization. In probabilistic terms, the AI verdict leans toward ALT for stability and catalyst clarity, while acknowledging OGEN's higher volatility and speculative potential—an assessment driven by data rather than any prediction of future price direction.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a Hold and OGEN is a Hold.
ALT in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 10, 2026
ALT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 37 of 42 cases where ALT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ALT's RSI Oscillator exited the oversold zone, 37 of 45 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 70 cases where ALT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for ALT just turned positive on November 02, 2026. Looking at past instances where ALT's MACD turned positive, the stock continued to rise in 36 of 46 cases over the following month. The odds of a continued upward trend are 78%.
Following a +7.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALT advanced for three days, in 204 of 256 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALT as a result. In 79 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for ALT entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. ALT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.853) is normal, around the industry mean (3.498). P/E Ratio (-2.737) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (1678.863) settles around the average of (130.981) among similar stocks. ALT's P/S Ratio (10000.000) is very high in comparison to the industry average of (440.869).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
OGEN's RSI Indicator remains in oversold zone for 9 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where OGEN advanced for three days, in 154 of 203 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
OGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OGEN as a result. In 87 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for OGEN turned negative on October 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 39 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for OGEN entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.429) is normal, around the industry mean (3.498). P/E Ratio (0.356) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. OGEN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ALT | OGEN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 7 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 94 Overvalued | 61 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 100 | |
PRICE GROWTH RATING 1..100 | 83 | 85 | |
P/E GROWTH RATING 1..100 | 16 | 1 | |
SEASONALITY SCORE 1..100 | 75 | 23 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
OGEN's Valuation (61) in the Biotechnology industry is somewhat better than the same rating for ALT (94) in the Miscellaneous Commercial Services industry. This means that OGEN’s stock grew somewhat faster than ALT’s over the last 12 months.
OGEN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ALT (100) in the Miscellaneous Commercial Services industry. This means that OGEN’s stock grew similarly to ALT’s over the last 12 months.
ALT's SMR Rating (96) in the Miscellaneous Commercial Services industry is in the same range as OGEN (100) in the Biotechnology industry. This means that ALT’s stock grew similarly to OGEN’s over the last 12 months.
ALT's Price Growth Rating (83) in the Miscellaneous Commercial Services industry is in the same range as OGEN (85) in the Biotechnology industry. This means that ALT’s stock grew similarly to OGEN’s over the last 12 months.
OGEN's P/E Growth Rating (1) in the Biotechnology industry is in the same range as ALT (16) in the Miscellaneous Commercial Services industry. This means that OGEN’s stock grew similarly to ALT’s over the last 12 months.
| ALT | OGEN | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 82% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 77% | 2 days ago 76% |
| Momentum ODDS (%) | 1 day ago 88% | 3 days ago 90% |
| MACD ODDS (%) | 1 day ago 78% | 3 days ago 90% |
| TrendWeek ODDS (%) | 1 day ago 87% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 86% | 1 day ago 90% |
| Advances ODDS (%) | 3 days ago 80% | 3 days ago 76% |
| Declines ODDS (%) | 1 day ago 88% | 1 day ago 90% |
| BollingerBands ODDS (%) | 1 day ago 88% | 1 day ago 85% |
| Aroon ODDS (%) | 1 day ago 89% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALT’s FA Score shows that 1 FA rating(s) are green while OGEN’s FA Score has 1 green FA rating(s).
- ALT’s FA Score: 1 green, 4 red.
- OGEN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALT’s TA Score shows that 5 TA indicator(s) are bullish while OGEN’s TA Score has 4 bullish TA indicator(s).
- ALT’s TA Score: 5 bullish, 3 bearish.
- OGEN’s TA Score: 4 bullish, 4 bearish.
Price Growth
ALT (@Biotechnology) experienced а -8.96% price change this week, while OGEN (@Biotechnology) price change was -7.30% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
ALT is expected to report earnings on Nov 12, 2026.
OGEN is expected to report earnings on Nov 13, 2026.
Industries' Descriptions
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ALT and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALT has been loosely correlated with OGEN. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ALT jumps, then OGEN could also see price increases.
| Ticker / NAME | Correlation To ALT | 1D Price Change % | ||
|---|---|---|---|---|
| ALT | 100% | -0.52% | ||
| OGEN - ALT | 54% Loosely correlated | -0.58% | ||
| DNLI - ALT | 45% Loosely correlated | -0.60% | ||
| EDIT - ALT | 45% Loosely correlated | -4.99% | ||
| FLNA - ALT | 45% Loosely correlated | -0.04% | ||
| INDP - ALT | 45% Loosely correlated | +10.69% | ||
More | ||||
OGEN and
Correlation & Price change
A.I.dvisor indicates that over the last year, OGEN has been loosely correlated with CDIO. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if OGEN jumps, then CDIO could also see price increases.
| Ticker / NAME | Correlation To OGEN | 1D Price Change % | ||
|---|---|---|---|---|
| OGEN | 100% | -0.58% | ||
| CDIO - OGEN | 38% Loosely correlated | +3.23% | ||
| MGX - OGEN | 36% Loosely correlated | +8.04% | ||
| UNCY - OGEN | 34% Loosely correlated | +3.28% | ||
| GOVX - OGEN | 32% Poorly correlated | -19.28% | ||
| SRPT - OGEN | 30% Poorly correlated | +1.58% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| CRYPTO / NAME | Price $ | Chg $ | Chg % |
| NFP.X | 0.000212 | 0.000082 | +62.46% |
| NFPrompt cryptocurrency | |||
| GAL.X | 0.790902 | 0.007807 | +1.00% |
| Galatasaray Fan Token cryptocurrency | |||
| HBAR.X | 0.065461 | -0.000111 | -0.17% |
| Hedera cryptocurrency | |||
| USDP.X | 0.993555 | -0.003286 | -0.33% |
| Pax Dollar cryptocurrency | |||
| ZEN.X | 4.805079 | -0.138205 | -2.80% |
| Horizen cryptocurrency | |||